Angiotensin II antagonists - an assessment of their acute toxicity

Autor:	Dagmar Prasa, Petra Hoffmann-Walbeck, Dieter Genser, Elke Färber, Michael Deters, Alessandro Ceschi, Carola Seidel, Susanne Barth, Uwe Stedtler
Rok vydání:	2013
Předmět:	Adult Male medicine.medical_specialty Poison Control Centers Time Factors Pharmacology Toxicology Irbesartan Internal medicine Germany medicine Humans Antihypertensive Agents Retrospective Studies business.industry Poisoning Eprosartan General Medicine Middle Aged Angiotensin II Losartan Valsartan Child Preschool Median body Female Telmisartan Drug Overdose Hypotension business Olmesartan Angiotensin II Type 1 Receptor Blockers medicine.drug
Zdroj:	Clinical toxicology (Philadelphia, Pa.). 51(5)
ISSN:	1556-9519
Popis:	In Germany, increasing prescription rates of angiotensin II antagonists resulted in rising enquiries to Poisons Information Centres (PICs) during the last decade. Therefore, we aimed to assess their acute toxicity for deriving triage recommendations.An observational case series with data collected retrospectively from eight PICs in Austria, Germany and Switzerland. Inclusion criteria were monoexposure, defined dose, and documented follow-up.In total, 206 cases of exposures to angiotensin II antagonists were included (candesartan, 94; eprosartan, 3; irbesartan, 20; losartan, 26; olmesartan, 16; telmisartan, 18; and valsartan, 29). The median dose expressed as a multiple of their maximum daily dose for adults adjusted to body weight (MDDw) was 2.3 in children and 6.8 in adults. Patients involved were 150 children with a median age of 2 years and a median body weight of 13 kg and 56 adults with a median age of 47 years and a median body weight of 70 kg. Most children remained asymptomatic (82.7%), 16.7% developed minor symptoms. Only once, a low blood pressure of 60/40 mm Hg required intravenous fluids after ingestion of a 8.75-fold MDDw of candesartan by a 2.5-year-old toddler. Among adults, 53.6% remained asymptomatic while almost half of the patients suffered from minor (37.5%) or moderate (8.9%) symptoms.As no or only minor symptoms were observed after ingestion of less than a fivefold MDDw in both children and adults, only symptomatic patients and those who have ingested a fivefold MDDw or higher dose should be referred for medical assessment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4edc1d6add6959fbcd3209dffe78dfab https://pubmed.ncbi.nlm.nih.gov/23692319 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.